Arrowstreet Capital
EBS icon

Arrowstreet Capital’s Emergent Biosolutions EBS Stock Holding History

Arrowstreet Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-54,835
Closed -$678K – 1916
2025
Q4 		$678K Buy
54,835
+21,128
+63% +$226K ﹤0.01% 1634
2025
Q3 		$297K Buy
+33,707
New +$262K ﹤0.01% 1764
2022
Q3 		– Sell
-15,945
Closed -$495K – 1320
2022
Q2 		$495K Buy
+15,945
New +$544K ﹤0.01% 1070
2019
Q1 		– Sell
-81,093
Closed -$4.81M – 1765
2018
Q4 		$4.81M Buy
81,093
+26,293
+48% +$1.69M 0.01% 585
2018
Q3 		$3.61M Buy
54,800
+27,608
+102% +$1.61M 0.01% 571
2018
Q2 		$1.37M Sell
27,192
-29,569
-52% -$1.54M ﹤0.01% 752
2018
Q1 		$2.99M Buy
+56,761
New +$2.83M 0.01% 672
2017
Q2 		– Sell
-290,266
Closed -$8.43M – 1129
2017
Q1 		$8.43M Buy
+290,266
New +$8.84M 0.03% 433
2016
Q4 		– Sell
-738,884
Closed -$23.3M – 1861
2016
Q3 		$23.3M Buy
738,884
+205,144
+38% +$5.96M 0.08% 256
2016
Q2 		$15M Buy
533,740
+223,380
+72% +$8.76M 0.05% 336
2016
Q1 		$11.3M Sell
310,360
-54,101
-15% -$1.91M 0.05% 340
2015
Q4 		$14.6M Sell
364,461
-16,562
-4% -$577K 0.07% 276
2015
Q3 		$10.9M Buy
381,023
+36,331
+11% +$1.2M 0.05% 322
2015
Q2 		$11.4M Buy
344,692
+112,638
+49% +$3.49M 0.06% 245
2015
Q1 		$6.67M Sell
232,054
-23,031
-9% -$661K 0.04% 355
2014
Q4 		$6.95M Buy
255,085
+69,999
+38% +$1.67M 0.04% 379
2014
Q3 		$3.94M Buy
185,086
+55,248
+43% +$1.27M 0.02% 444
2014
Q2 		$2.92M Sell
129,838
-3,951
-3% -$92K 0.02% 519
2014
Q1 		$3.38M Buy
133,789
+73,040
+120% +$1.84M 0.02% 524
2013
Q4 		$1.4M Buy
+60,749
New +$1.27M 0.01% 755

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Arrowstreet Capital's EBS Position: Q1 2026 in Review

Arrowstreet Capital sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 54,835 shares — an estimated $678K sold.

Arrowstreet Capital first reported a position in EBS in Q4 2013 and held it in 20 quarters. The position peaked at $23.3M in Q3 2016. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Arrowstreet Capital reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 54,835 Emergent Biosolutions shares in Q1 2026, an estimated $678K.
  • Arrowstreet Capital first reported a position in Emergent Biosolutions in Q4 2013 and held it in 20 quarters.
  • Arrowstreet Capital's Emergent Biosolutions position peaked at $23.3M in Q3 2016.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.